Funding Resources
Funding Overview
Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
Development
Contracts Management
Review Committees
Funding News |
Research
Anticonvulsant Screening
Program
Clinical Research
Counterterrorism
Epilepsy Research Web
Neural Interfaces Program
NIH Roadmap Research
Parkinson's Web
Resources for Scientists
Stem Cell Research
Translational Research
Traumatic Brain Injury
(TBI) Research
Technology Transfer
Office
NINDS is part of the
National Institutes of
Health
Investigators at the National Institute of Neurological Disorders and Stroke (NINDS) are seeking patients with Menkes disease-a genetic disorder affecting the metabolism of copper-for a study of early copper histidine therapy. In the study, researchers will evaluate the effects of early copper histidine in patients with Menkes disease, and correlate specific molecular defects with responses to treatment. Eligible patients must be diagnosed at or shortly after birth as having Menkes disease. The study will be conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All study-related expenses will be paid by the NIH. The study will be carried out under testing and safety standards of the U.S. Department of Health and Human Services. For more information, physicians should send a referral letter and a copy of the patient's recent medical records to Dr. Stephen Kaler, NINDS, NIH, Building 31, Room 1B-03, 31 Center Drive MSC 2082, Bethesda, MD 20892-2082; telephone: (301) 496-8368; fax: (301) 402-1073; email: sgk@box-s.nih.gov.
This content has been adapted from the original NINDS Notes publication. For the most up-to-date funding information, please visit the Funding Opportunities section of the NINDS web site. For the most recent information on NINDS studies, please visit the NINDS Patient Recruitment web site.